

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1 -106. (canceled).

107. (currently amended) A solid formulation, said formulation comprising 35-45 % w/w of 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide L-malate and a pharmaceutically acceptable carrier therefor comprising 10 – 86 % w/w of one or more pharmaceutically acceptable diluents, 2 – 20 % w/w of one or more pharmaceutically acceptable binders, 2 – 20 % w/w of one or more pharmaceutically acceptable disintegrants, and 1 – 10 % w/w of one or more pharmaceutically acceptable lubricants, based on the total weight of the formulation, wherein said formulation has a bulk density of at least ~~about~~ 0.50 kg/L.

108 - 110. (canceled).

111. (currently amended) A solid formulation, said formulation comprising 10 – 16 % w/w of 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide L-malate, 65 – 80 % w/w mannitol, 5 – 10 % w/w croscarmellose sodium, 4 – 8 % w/w povidone and 1 – 2 % w/w magnesium stearate; wherein said formulation has a bulk density of at least ~~about~~ 0.50 kg/L.

112. (canceled)

113. (previously presented) The formulation of claim 107, wherein said formulation does not comprise a surfactant or a flow enhancer.

114. (canceled)

115. (currently amended) The formulation of claim 107, wherein said formulation has a bulk density of at least ~~about~~ 0.60 kg/L.

116. (currently amended) The formulation of claim 107, wherein said formulation has a bulk density of at least ~~about~~ 0.64 kg/L.

117. (previously presented) The formulation of claim 107, wherein said formulation is in particulate form, and wherein no more than 55% of the particles have a size less than 250 microns.

118. (currently amended) A solid formulation comprising 40 % w/w of 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide L-malate, 47.5 % w/w mannitol, 6 % w/w croscarmellose sodium, 5 % w/w povidone and 1.5 % w/w magnesium stearate, wherein said formulation has a bulk density of at least ~~about~~ 0.50 kg/L.

119. (currently amended) A solid formulation comprising 15.2 % w/w of 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide L-malate, 72.7 % w/w mannitol, 6 % w/w croscarmellose sodium, 5.1 % w/w povidone and 1 % w/w magnesium stearate, wherein said formulation has a bulk density of at least ~~about~~ 0.50 kg/L.

120. (New) A solid formulation, said formulation comprising 35-45 % w/w of 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide L-malate and a pharmaceutically acceptable carrier therefor comprising 10 – 86 % w/w of one or more pharmaceutically acceptable diluents, 2 – 20 % w/w of one or more pharmaceutically acceptable binders, 2 – 20 % w/w of one or more pharmaceutically acceptable disintegrants, and 1 – 10 % w/w of one or more pharmaceutically acceptable lubricants, based on the total weight of the formulation, wherein said solid formulation has a bulk density of at least 0.50 kg/L and does not comprise a surfactant or flow enhancer.

121. (New) The solid formulation of claim 121, wherein the formulation comprises 40 % w/w of 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide L-malate, 47.5 % w/w mannitol, 6 % w/w croscarmellose sodium, 5 % w/w povidone and 1.5 % w/w magnesium stearate.